Cisplatina 2024
Researchers develop a risk prediction model for cisplatin-induced kidney damage News-Medical.Net
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial Nature.com
Frontline Pembrolizumab Plus Cabozantinib Elicits Responses in Cisplatin-Ineligible Urothelial Carcinoma OncLive
Cancer drug shortage: FDA will allow imports of cisplatin from China NBC News